Organization
Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO)
4 abstracts
Abstract
A phase II open‐label study with atezolizumab (atezo) in combination with bevacizumab (bev) in patients (pts) with advanced chemotherapy-resistant colorectal cancer (CRC) and MSI‐like molecular signature: The MoTriColor Consortium CT3 study.Org: Milano, MI, Italy, Napoli, Italy, Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, L?Hospitalet De Llobregat,
Abstract
Clinical and genomic characterization of early-onset pancreatic cancer.Org: Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Hospital Universitari Vall d'Hebron Research Institute, Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Preclinical and Translational Research Program, Cancer Genomics Group,
Abstract
New ESMO scale for clinical actionability of molecular targets (ESCAT) for gliomas based on a multicentric real world data cohort using next-generation sequencing (NGS).Org: Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Hospital Universitario 12 de Octubre, Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d´Hebron Institute of Oncology (VHIO), Institut Catala d'Oncologia Badalona,
Abstract
The impact of Covid-19 pandemic on breast cancer multidisciplinary management at the Vall d'Hebron University Hospital.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d´Hebron Institute of Oncology (VHIO),